Key result
SGLT2 inhibitors lower systolic blood pressure by ~3 mmHg and confer multifaceted cardiorenal protection.
Why the study?
The antihypertensive mechanism of SGLT2 inhibitors has been traditionally attributed to osmotic diuresis, but emerging evidence reveals multifaceted mechanisms beyond diuresis in CKM syndrome patients.
Do SGLT2 inhibitors reduce blood pressure and provide cardiorenal protection in patients with cardiovascular-kidney-metabolic syndrome?
Do SGLT2 inhibitors reduce blood pressure and provide cardiorenal protection in patients with cardiovascular-kidney-metabolic syndrome?
SGLT2 inhibitors offer multifaceted antihypertensive effects that provide cardiorenal protection in patients with cardiovascular-kidney-metabolic syndrome.
May support BP lowering with SGLT2i in T2DM and CKM syndrome; extends mechanistic insights beyond diuresis but leaves open prospective validation.
The antihypertensive mechanism of sodium-glucose cotransporter 2 (SGLT2) inhibitors has been traditionally attributed to osmotic diuresis. However, emerging evidence reveals multifaceted mechanisms beyond diuresis, including regulation of the renin-angiotensin-aldosterone system, sympathetic nervous system suppression, ion homeostasis restoration, anti-inflammatory/antioxidant actions, weight loss and improved vascular function. These synergistic pathways collectively reduce blood pressure and provide cardiorenal protection in cardiovascular-kidney-metabolic (CKM) syndrome patients. Elucidating these multi-target antihypertensive effects holds critical implications for optimizing therapeutic strategies, mitigating cardiorenal risks and establishing SGLT2 inhibitors as adjunctive antihypertensive therapy in CKM syndrome patients.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2025) conducted a review in Cardiovascular-kidney-metabolic (CKM) syndrome and hypertension. SGLT2 inhibitors was evaluated. SGLT2 inhibitors reduce systolic and diastolic blood pressure by 2.0-4.5 and 1.0-2.0 mmHg respectively in T2DM patients, providing cardiorenal protection through multifaceted mechanisms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: